

Serum Exchange #548

February 3, 2016

The results for **Serum Exchange 548 (sera 1185 - 1188)**, are summarized in Tables 16-21 and individual laboratory results by method are listed

in Tables 22-31. Sera positive to 5C, A25, and B13 were examined in this study.

| 1185 | | method | #labs | B57 | B46 | B62 | B63 | B75 | B50 | B56 | B55 | B13 | B35 | B49 | B53 | B58 | B77 | B37 | B41 | B44 | A1 | A23 | A25 | A29 |
|---------|---------|--------|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| class I | NIH-Std | 4 | 75 | | 75 | | | | | | | | | | | | | | | | | | | |
| | NIH-Ext | 3 | 100 | 33 | 100 | 100 | 100 | | | | | | | | | | 33 | | | | | | | |
| | AHG | 2 | 50 | 50 | 50 | 50 | | | 50 | 50 | 50 | | | | | | | | | | | | | |
| | Luminex | 23 | 96 | 100 | 96 | 96 | 96 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 96 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| | Flow | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | |
| | ELISA | 2 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | | | 100 | 100 | 100 | 100 | 50 | 50 | 50 |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | |
| | Other | 3 | 67 | 67 | | 67 | 67 | 67 | 67 | 67 | | 67 | 67 | 67 | 67 | 67 | 67 | 33 | 33 | 33 | 33 | 33 | 33 | 33 |

Sample 1185 was reported to be strongly positive to B57. Additional reactivity to a number of 5C specificities, as well as to B13, B55, and B56 was also strongly detected by various methods. Reactivity to 1C and 12C specificities was reported by Luminex and ELISA. Class II reactivity to DR3 (DR17 and DR18) was reported by Luminex and Luminex PRA. In addition, Luminex reported moderate to weak reactivity to DR52, DR13, and DR14. Several labs noted weak reactivity to DRB3*01:01.

| 1185 | | method | #labs | DR18 | DR17 | DR52 | DR13 | DR14 | DR11 |
|----------|---------|--------|---------------------------|------|------|------|------|------|------|
| class II | NIH-Ext | 1 | no specificities assigned | | | | | | |
| | Luminex | 24 | 95 | 89 | 74 | 37 | 37 | 21 | |
| | Flow | 1 | no specificities assigned | | | | | | |
| | C1q | 1 | NT | | | | | | |
| | Other | 2 | 50 | 50 | | | | | |

| 1186 | | method | #labs | A25 | B57 | B58 | B17 | A26 | A32 | A33 | A2 | A203 | A66 | A6601 | A6602 | A11 | A1101 | A1102 | A34 | A68 |
|---------|---------|--------|--------------|-----|-----|-----|-----|-----|-----|-----|----|------|-----|-------|-------|-----|-------|-------|-----|-----|
| class I | NIH-Std | 4 | 25 | 25 | | 25 | | | | | | | | | | | | | | |
| | NIH-Ext | 3 | 67 | 67 | 33 | | | | | 33 | | | | | | | | | | |
| | AHG | 2 | 100 | 50 | 50 | 50 | 50 | 50 | 50 | | 50 | | | 50 | | | | | | |
| | Luminex | 24 | 96 | 96 | 96 | | 92 | 96 | 96 | 96 | 21 | 75 | 33 | 33 | 75 | 29 | 29 | 96 | 96 | |
| | Flow | 1 | no consensus | | | | | | | | | | | | | | | | | |
| | ELISA | 2 | 100 | 100 | 100 | | 100 | 50 | 50 | 100 | | | 50 | | | 50 | | 50 | 50 | |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | |
| | Other | 3 | 67 | 67 | 67 | | 33 | 67 | 67 | 67 | | | 67 | | | 67 | | 67 | 67 | |

For **sample 1186**, anti-A25, -B57, and -B58 reactivity was reported by all methods. In addition, reactivity to A2, 10C, and 1C specificities was reported by various methods. Luminex, ELISA and Luminex PRA also reported reactivity to a number of 5C specificities. For class II, reactivity to DQ3 (DQ7, DQ8, and DQ9), DR7, and DR9 was reported by Luminex and Luminex PRA. Strong anti-DR12 and -DR52 reactivity was also reported by Luminex. Several Luminex labs reported allele level reactivity to DRB3*01:01 and DRB3*03:01, and DQA1*02.

| 1186 | | method | #labs | DQ7 | DQ8 | DQ9 | DR7 | DR9 | DR12 | DR52 | DPw5 | DP10 | DP9 | DPw1 | DP13 | DP14 |
|----------|---------|--------|---------------------------|-----|-----|-----|-----|-----|------|------|------|------|-----|------|------|------|
| class II | NIH-Ext | 1 | no specificities assigned | | | | | | | | | | | | | |
| | Luminex | 24 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 95 | 26 | 21 | 21 | 21 | 16 | 16 |
| | Flow | 1 | no specificities assigned | | | | | | | | | | | | | |
| | C1q | 1 | NT | | | | | | | | | | | | | |
| | Other | 2 | 50 | 50 | 50 | 50 | 50 | | | | | | | | | |

| 1187 | method | #abs | B13 | B41 | B44 | B45 | B49 | A30 | A31 | B50 | B51 | B47 | B60 | B61 | B59 | B52 | B53 | Cw18 | Cw6 | B7 | B63 | B64 | B77 | A32 | |
|---------|---------|------|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|----|-----|-----|-----|-----|--|
| class I | NIH-Std | 4 | 100 | | | | | | | | | | | | | | | | | 25 | | | | | |
| | NIH-Ext | 3 | 33 | | | | | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 100 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | | | | | | | | | | | | | | |
| | Luminex | 24 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | 100 | 96 | 96 | 88 | 79 | 29 | 50 | 83 | | | | 25 | | |
| | Flow | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | |
| | ELISA | 2 | 100 | 100 | 100 | 100 | 50 | 50 | 50 | 50 | | 50 | 50 | 50 | 50 | | | | | | | | | | |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | |
| | Other | 3 | 67 | 67 | 33 | 67 | 67 | 67 | 67 | 67 | 33 | 67 | 67 | 67 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | 33 | | 33 | |

| 1187 | method | #abs | DQ2 | DR12 | DR7 | DR9 | DR52 | DR18 | DR17 | DR13 | DR14 | DQ9 | DQ7 | DR11 |
|----------|---------|------|---------------------------|------|-----|-----|------|------|------|------|------|-----|-----|------|
| class II | NIH-Ext | 1 | no specificities assigned | | | | | | | | | | | |
| | Luminex | 24 | 100 | 100 | 100 | 100 | 100 | 79 | 37 | 32 | 21 | 21 | 21 | 11 |
| | Flow | 1 | no specificities assigned | | | | | | | | | | | |
| | C1q | 1 | no consensus | | | | | | | | | | | |
| | Other | 2 | 50 | 50 | 50 | 50 | | | | | | | | |

Sample 1187 was found to be strongly positive to B13. Additional reactivity to B44, B45, B49, A30, A31, and a number of 7C specificities were reported by AHG, Luminex, ELISA and Luminex PRA. Class II reactivity to DQ2, DR7, DR9, and DR12 was reported by Luminex and Luminex PRA. In addition, Luminex reported strong anti-DR52 and -DR18 reactivity. Allele level reactivity to DQA1*02 was also reported by several Luminex labs.

| 1188 | method | #abs | B13 | B61 | B60 | B41 | B47 | B49 | B50 | B45 | B44 | B51 | B52 | B57 | B59 | B7 | B38 | B62 | B72 | B53 | B35 | B63 | B75 | | |
|---------|---------|------|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| class I | NIH-Std | 4 | 75 | | | | | | | | | | | | | | | | | | | | | | |
| | NIH-Ext | 3 | 100 | 67 | 33 | | | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 100 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | | | | | | | | | | | | | | |
| | Luminex | 24 | 100 | 96 | 96 | 96 | 100 | 100 | 96 | 100 | 96 | 96 | 96 | 92 | 96 | 92 | 92 | 92 | 92 | 92 | 92 | 88 | 88 | | |
| | Flow | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | |
| | ELISA | 2 | 100 | 100 | 50 | 100 | 50 | 100 | 100 | 100 | 100 | 50 | 50 | 50 | 50 | | 50 | 50 | 50 | 50 | 50 | 50 | 100 | | |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | |
| | Other | 3 | 67 | 67 | 67 | 33 | 67 | 67 | 67 | 67 | | 33 | 33 | 33 | 33 | 33 | | | | | | | | | |
| 1188 | method | #abs | B37 | B58 | B78 | B18 | A43 | A26 | A66 | B71 | B77 | B39 | B56 | B81 | B73 | B46 | B12 | B27 | B48 | B40 | B21 | B55 | | | |
| | AHG | 2 | | | | | | | | | | | | | | | 50 | | | 50 | 50 | | | | |
| | Luminex | 24 | 88 | 71 | 59 | 38 | 42 | | | 92 | 92 | 83 | 75 | 75 | 54 | 42 | | | | | | | | | |
| | ELISA | 2 | 50 | 50 | 50 | | | 50 | 50 | | | | | | | | | 50 | 50 | | | 50 | | | |
| | Other | 3 | | | | 33 | | | | | | | | | | | | | | | | | | | |

For **sample 1188**, strong reactivity to B13 was reported by all methods. Additional reactivity to B44, B45, 5C and 7C specificities was reported by various methods. Class II reactivity to DR4 was reported by Luminex and Luminex PRA. In addition, strong reactivity to DR53 was reported by Luminex.

| 1188 | method | #abs | DR4 | DR53 | DP14 | DPw5 | DR16 |
|----------|---------|------|---------------------------|------|------|------|------|
| class II | NIH-Ext | 1 | no specificities assigned | | | | |
| | Luminex | 24 | 100 | 100 | 11 | 11 | 11 |
| | Flow | 1 | no specificities assigned | | | | |
| | C1q | 1 | NT | | | | |
| | Other | 2 | 50 | | | | |

NEXT MAILING DATE: March 2, 2016
Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed

The results for **Serum Exchange 549 (sera 1189 - 1192)**, are summarized in Tables 32-38 and individual laboratory results by method are listed in Tables 39-50. Sera strongly positive to A2, A19, and A29 were examined in this study.

Sample 1189 was reported to be strongly positive to A2 by all methods. In addition, reactivity to A28 (A68 and A69) and a number of 5C specificities, including B17 (B57 and B58), was detected by various methods. Luminex and ELISA also reported strong reactivity to A32, B13, and 1C specificities. Additional strong reactivity to a number of C-locus specificities (Cw2, Cw4, Cw5, Cw6, Cw15, Cw17, and Cw18) was

| 1192 | method | #labs | A29 | A30 | A31 | A26 | A33 | A1 | A80 | A74 | A66 | A6601 | A34 | A10 | B42 | A36 | A3 | A11 | B7 | B55 | B81 | B35 | |
|------|---------|-------|---------------------------|---------|-------|-------|-----|-----|-----|-------|-----|-------|-------|-------|-----|-------|-----|-----|-----|-----|-----|-----|----|
| | | | class I | NIH-Std | 3 | 67 | | | | | | | | | | | | | | | | | |
| | NIH-Ext | 2 | 100 | 50 | | | | | | | | | | | | | | | | | | | |
| | AHG | 3 | 100 | 67 | 33 | 67 | 33 | 33 | 33 | 67 | 33 | 33 | | 33 | | | | | | | | | |
| | Luminex | 25 | 96 | 100 | 100 | 96 | 100 | 96 | 96 | 92 | 80 | 28 | 100 | | 72 | 96 | 96 | 72 | 88 | 72 | 64 | 50 | |
| | Flow | 1 | no specificities assigned | | | | | | | | | | | | | | | | | | | | |
| | ELISA | 2 | 100 | 50 | 50 | 100 | 50 | 50 | 50 | 100 | 50 | 50 | 50 | | 50 | 50 | 50 | 50 | 50 | 50 | 50 | | |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | | | | |
| | Other | 2 | 50 | | | 50 | | | | | | | | | 50 | | | | | | | | 50 |
| 1192 | method | #labs | B54 | A43 | A1101 | A1102 | B67 | B56 | B82 | A6602 | B27 | B48 | B8101 | B2708 | B60 | B8201 | A25 | B41 | B51 | B52 | B53 | | |
| | | | AHG | 3 | | | | | | | | | | | | | | | 33 | | | | |
| | Luminex | 25 | 20 | 100 | 24 | 24 | 72 | 56 | 48 | 32 | 20 | 20 | 12 | 8 | 8 | 8 | | | | | | | |
| | Other | 2 | 50 | | | | | | | | | | | | | | | 50 | 50 | 50 | 50 | | |

| 1192 | method | #labs | DR7 | DR9 | DQ7 | DQ8 | DQ9 | DQ4 | DPw1 | DPw5 | DP19 | DP14 | DP13 | DP9 | DP11 | DP17 | DQ2 | DP10 | DPw3 | DPw6 | DR18 | DP18 | DP401 | DPw4 | DP15 | DP20 | |
|------|---------|-------|---------------------------|---------|-----|--------------|-----|-----|------|------|------|------|------|-----|------|------|-----|------|------|------|------|------|-------|------|------|------|--|
| | | | class II | NIH-Ext | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | |
| | Luminex | 8 | 100 | 100 | 95 | 95 | 95 | 90 | 85 | 85 | 80 | 75 | 75 | 70 | 60 | 60 | 60 | 55 | 55 | 45 | 25 | 25 | 20 | 20 | 15 | 15 | |
| | Flow | 1 | no specificities assigned | | | | | | | | | | | | | | | | | | | | | | | | |
| | C1q | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | | | |
| | Other | 2 | 50 | 50 | 50 | 50 | 50 | 50 | | | | | | | | | | | | | | | | | | | |

Table 16. Summary of the 548th Serum Exchange (Serum #1185-1188) by NIH-Standard and NIH-Extended - class I

| Method: NIH-Standard | | | | | | | | | | | |
|-----------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 4 typing Labs | | | 4 typing Labs | | | 4 typing Labs | | | 4 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| B57 | 75% | 100% | A25 | 25% | 100% | B13 | 100% | 100% | B13 | 75% | 89% |
| B62 | 75% | 100% | B17 | 25% | 100% | B7 | 25% | 60% | | | |
| B15 | 25% | 100% | B57 | 25% | 60% | | | | | | |
| B17 | 25% | 100% | | | | | | | | | |

| Method: NIH-Extended | | | | | | | | | | | |
|-----------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| B57 | 100% | 100% | B57 | 67% | 100% | B13 | 33% | 100% | B13 | 100% | 100% |
| B63 | 100% | 100% | A25 | 67% | 75% | | | | B61 | 67% | 100% |
| B75 | 100% | 100% | B58 | 33% | 100% | | | | B60 | 33% | 60% |
| B62 | 100% | 80% | A33 | 33% | 50% | | | | | | |
| B76 | 67% | 100% | | | | | | | | | |
| B46 | 33% | 100% | | | | | | | | | |
| B77 | 33% | 100% | | | | | | | | | |

Table 17. Summary of the 548th Serum Exchange (Serum #1185-1188) by Antiglobulin and C1q - class I

| Method: Antiglobulin | | | | | | | | | | | |
|-----------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| B15 | 50% | 100% | A25 | 100% | 100% | B13 | 100% | 100% | B13 | 100% | 100% |
| B17 | 50% | 100% | A26 | 50% | 100% | B41 | 50% | 100% | B21 | 50% | 100% |
| B21 | 50% | 100% | A32 | 50% | 100% | B49 | 50% | 75% | B40 | 50% | 100% |
| B46 | 50% | 100% | A6601 | 50% | 100% | B45 | 50% | 67% | B41 | 50% | 100% |
| B62 | 50% | 100% | B17 | 50% | 100% | A30 | 50% | 50% | B47 | 50% | 100% |
| B63 | 50% | 100% | B57 | 50% | 100% | B44 | 50% | 50% | B49 | 50% | 100% |
| B70 | 50% | 100% | B58 | 50% | 100% | B51 | 50% | 36% | B50 | 50% | 100% |
| B50 | 50% | 80% | A2 | 50% | 56% | A31 | 50% | 20% | B60 | 50% | 100% |
| B57 | 50% | 80% | | | | B50 | 50% | 20% | B61 | 50% | 100% |
| B55 | 50% | 60% | | | | | | | B45 | 50% | 67% |
| B56 | 50% | 50% | | | | | | | B12 | 50% | 56% |
| B7 | 50% | 50% | | | | | | | B44 | 50% | 50% |

| Method: C1q | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| no consensus | | | no consensus | | | no consensus | | | no consensus | | |

Table 18. Summary of the 548th Serum Exchange (Serum #1185-1188) by Other - class I

| *** Serum 1185 *** | | |
|--------------------|-----------|-----------|
| 3 typing Labs | | |
| Antigen | Consensus | Inclusion |
| B13 | 67% | 100% |
| B35 | 67% | 100% |
| B46 | 67% | 100% |
| B49 | 67% | 100% |
| B50 | 67% | 100% |
| B53 | 67% | 100% |
| B56 | 67% | 100% |
| B57 | 67% | 100% |
| B58 | 67% | 100% |
| B63 | 67% | 100% |
| B72 | 67% | 100% |
| B75 | 67% | 100% |
| B77 | 67% | 100% |
| A1 | 33% | 100% |
| A11 | 33% | 100% |
| A23 | 33% | 100% |
| A24 | 33% | 100% |
| A25 | 33% | 100% |
| A29 | 33% | 100% |
| A30 | 33% | 100% |
| A32 | 33% | 100% |
| A33 | 33% | 100% |
| A34 | 33% | 100% |
| A36 | 33% | 100% |
| A43 | 33% | 100% |
| A66 | 33% | 100% |
| A68 | 33% | 100% |
| A69 | 33% | 100% |
| B18 | 33% | 100% |
| B27 | 33% | 100% |
| B37 | 33% | 100% |
| B38 | 33% | 100% |
| B39 | 33% | 100% |
| B41 | 33% | 100% |
| B42 | 33% | 100% |
| B44 | 33% | 100% |

| *** Serum 1186 *** | | |
|--------------------|-----------|-----------|
| 3 typing Labs | | |
| Antigen | Consensus | Inclusion |
| A11 | 67% | 100% |
| A2 | 67% | 100% |
| A25 | 67% | 100% |
| A29 | 67% | 100% |
| A31 | 67% | 100% |
| A32 | 67% | 100% |
| A33 | 67% | 100% |
| A34 | 67% | 100% |
| A66 | 67% | 100% |
| A68 | 67% | 100% |
| A74 | 67% | 100% |
| B57 | 67% | 100% |
| B58 | 67% | 100% |
| A1 | 33% | 100% |
| A23 | 33% | 100% |
| A24 | 33% | 100% |
| A26 | 33% | 100% |
| A30 | 33% | 100% |
| A36 | 33% | 100% |
| A43 | 33% | 100% |
| A69 | 33% | 100% |
| A80 | 33% | 100% |
| B13 | 33% | 100% |
| B18 | 33% | 100% |
| B27 | 33% | 100% |
| B63 | 33% | 100% |
| B64 | 33% | 100% |
| B72 | 33% | 100% |
| B75 | 33% | 100% |
| B77 | 33% | 100% |
| CW15 | 33% | 100% |
| CW16 | 33% | 100% |
| CW17 | 33% | 100% |
| CW4 | 33% | 100% |

| *** Serum 1187 *** | | |
|--------------------|-----------|-----------|
| 3 typing Labs | | |
| Antigen | Consensus | Inclusion |
| A30 | 67% | 100% |
| A31 | 67% | 100% |
| B13 | 67% | 100% |
| B41 | 67% | 100% |
| B45 | 67% | 100% |
| B47 | 67% | 100% |
| B49 | 67% | 100% |
| B50 | 67% | 100% |
| B60 | 67% | 100% |
| B61 | 67% | 100% |
| A32 | 33% | 100% |
| B44 | 33% | 100% |
| B51 | 33% | 100% |
| B52 | 33% | 100% |
| B53 | 33% | 100% |
| B59 | 33% | 100% |
| B63 | 33% | 100% |
| B64 | 33% | 100% |
| B7 | 33% | 100% |
| CW18 | 33% | 100% |
| CW6 | 33% | 100% |

| *** Serum 1188 *** | | |
|--------------------|-----------|-----------|
| 3 typing Labs | | |
| Antigen | Consensus | Inclusion |
| B13 | 67% | 100% |
| B45 | 67% | 100% |
| B47 | 67% | 100% |
| B49 | 67% | 100% |
| B50 | 67% | 100% |
| B60 | 67% | 100% |
| B61 | 67% | 100% |
| A1 | 33% | 100% |
| A11 | 33% | 100% |
| A30 | 33% | 100% |
| A31 | 33% | 100% |
| A32 | 33% | 100% |
| A33 | 33% | 100% |
| B18 | 33% | 100% |
| B41 | 33% | 100% |
| B51 | 33% | 100% |
| B52 | 33% | 100% |
| B57 | 33% | 100% |
| B59 | 33% | 100% |
| B64 | 33% | 100% |
| B7 | 33% | 100% |
| CW1 | 33% | 100% |
| CW12 | 33% | 100% |
| CW16 | 33% | 100% |
| CW6 | 33% | 100% |
| CW7 | 33% | 100% |

Table 19. Summary of the 548th Serum Exchange (Serum #1185-1188) by Luminex - class I

| *** Serum 1185 *** | | |
|--------------------|-----------|-----------|
| 23 typing Labs | | |
| Antigen | Consensus | Inclusion |
| A1 | 100% | 100% |
| A23 | 100% | 100% |
| A25 | 100% | 100% |
| A29 | 100% | 100% |
| A36 | 100% | 100% |
| A43 | 100% | 100% |
| A80 | 100% | 100% |
| B13 | 100% | 100% |
| B35 | 100% | 100% |
| B37 | 100% | 100% |
| B41 | 100% | 100% |
| B42 | 100% | 100% |
| B44 | 100% | 100% |
| B45 | 100% | 100% |
| B46 | 100% | 100% |
| B49 | 100% | 100% |
| B50 | 100% | 100% |
| B51 | 100% | 100% |
| B52 | 100% | 100% |
| B53 | 100% | 100% |
| B55 | 100% | 100% |
| B56 | 100% | 100% |
| B58 | 100% | 100% |
| B59 | 100% | 100% |
| B67 | 100% | 100% |
| B38 | 100% | 80% |
| B57 | 96% | 100% |
| B62 | 96% | 100% |
| B63 | 96% | 100% |
| B71 | 96% | 100% |
| B75 | 96% | 100% |
| B76 | 96% | 100% |
| B77 | 96% | 100% |
| CW15 | 96% | 100% |
| CW18 | 96% | 100% |
| CW4 | 96% | 100% |

| *** Serum 1186 *** | | |
|--------------------|-----------|-----------|
| 24 typing Labs | | |
| Antigen | Consensus | Inclusion |
| A2 | 96% | 100% |
| A25 | 96% | 100% |
| A29 | 96% | 100% |
| A31 | 96% | 100% |
| A32 | 96% | 100% |
| A33 | 96% | 100% |
| A34 | 96% | 100% |
| A68 | 96% | 100% |
| A74 | 96% | 100% |
| B57 | 96% | 100% |
| B58 | 96% | 100% |
| B63 | 96% | 100% |
| A69 | 96% | 75% |
| A26 | 92% | 100% |
| A43 | 92% | 100% |
| A30 | 83% | 50% |
| A11 | 75% | 100% |
| A66 | 75% | 100% |
| A24 | 71% | 50% |
| A36 | 67% | 100% |
| B75 | 67% | 100% |
| A23 | 62% | 100% |
| B62 | 62% | 100% |
| B76 | 58% | 100% |
| B77 | 58% | 100% |
| A1 | 50% | 100% |
| A6601 | 33% | 100% |
| A6602 | 33% | 100% |
| A1101 | 29% | 100% |
| A1102 | 29% | 100% |
| B13 | 29% | 100% |
| A203 | 21% | 100% |
| A2403 | 21% | 100% |

| *** Serum 1187 *** | | |
|--------------------|-----------|-----------|
| 24 typing Labs | | |
| Antigen | Consensus | Inclusion |
| A30 | 100% | 100% |
| A31 | 100% | 100% |
| B13 | 100% | 100% |
| B41 | 100% | 100% |
| B45 | 100% | 100% |
| B47 | 100% | 100% |
| B49 | 100% | 100% |
| B50 | 100% | 100% |
| B44 | 100% | 88% |
| B60 | 96% | 100% |
| B61 | 96% | 100% |
| B51 | 88% | 86% |
| B59 | 88% | 75% |
| CW6 | 83% | 100% |
| B52 | 79% | 40% |
| CW18 | 50% | 100% |
| B53 | 29% | 100% |
| B77 | 25% | 100% |

| *** Serum 1188 *** | | |
|--------------------|-----------|-----------|
| 24 typing Labs | | |
| Antigen | Consensus | Inclusion |
| B13 | 100% | 100% |
| B45 | 100% | 100% |
| B47 | 100% | 100% |
| B49 | 100% | 100% |
| B41 | 96% | 100% |
| B44 | 96% | 100% |
| B50 | 96% | 100% |
| B51 | 96% | 100% |
| B60 | 96% | 100% |
| B61 | 96% | 100% |
| B27 | 96% | 86% |
| B7 | 96% | 67% |
| B57 | 96% | 50% |
| B62 | 92% | 100% |
| B76 | 92% | 100% |
| B77 | 92% | 100% |
| B72 | 92% | 80% |
| B52 | 92% | 75% |
| B53 | 92% | 75% |
| B71 | 92% | 75% |
| B35 | 92% | 67% |
| B59 | 92% | 67% |
| B38 | 92% | 50% |
| B63 | 88% | 100% |
| B75 | 88% | 100% |
| B37 | 88% | 50% |
| B39 | 83% | 75% |
| B48 | 83% | 67% |
| B56 | 75% | 100% |
| B81 | 75% | 75% |
| B58 | 71% | 33% |
| B73 | 54% | 100% |
| B78 | 50% | 100% |
| A43 | 42% | 100% |
| B46 | 42% | 100% |
| B18 | 38% | 100% |

Table 20. Summary of the 548th Serum Exchange (Serum #1185-1188) by Flow Cytometry and ELISA - class I

| Method: Flow Cytometry | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| no consensus | | | no consensus | | | no consensus | | | no consensus | | |

| Method: ELISA | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| A1 | 100% | 100% | A25 | 100% | 100% | B13 | 100% | 100% | B13 | 100% | 100% |
| B13 | 100% | 100% | A26 | 100% | 100% | B41 | 100% | 100% | B41 | 100% | 100% |
| B35 | 100% | 100% | B57 | 100% | 100% | B44 | 100% | 100% | B44 | 100% | 100% |
| B37 | 100% | 100% | B58 | 100% | 100% | B45 | 100% | 100% | B45 | 100% | 100% |
| B41 | 100% | 100% | A2 | 100% | 8% | A30 | 50% | 100% | B50 | 100% | 100% |
| B44 | 100% | 100% | A1 | 50% | 100% | A31 | 50% | 100% | B61 | 100% | 100% |
| B45 | 100% | 100% | A11 | 50% | 100% | B47 | 50% | 100% | B75 | 100% | 100% |
| B46 | 100% | 100% | A29 | 50% | 100% | B49 | 50% | 100% | B49 | 100% | 75% |
| B49 | 100% | 100% | A31 | 50% | 100% | B50 | 50% | 100% | A26 | 50% | 100% |
| B50 | 100% | 100% | A32 | 50% | 100% | B59 | 50% | 100% | A66 | 50% | 100% |
| B52 | 100% | 100% | A33 | 50% | 100% | B60 | 50% | 100% | B27 | 50% | 100% |
| B53 | 100% | 100% | A34 | 50% | 100% | B61 | 50% | 100% | B35 | 50% | 100% |
| B55 | 100% | 100% | A66 | 50% | 100% | | | | B37 | 50% | 100% |
| B56 | 100% | 100% | A68 | 50% | 100% | | | | B38 | 50% | 100% |
| B57 | 100% | 100% | A69 | 50% | 100% | | | | B47 | 50% | 100% |
| B58 | 100% | 100% | A74 | 50% | 100% | | | | B48 | 50% | 100% |
| B62 | 100% | 100% | B46 | 50% | 100% | | | | B51 | 50% | 100% |
| B63 | 100% | 100% | B62 | 50% | 100% | | | | B52 | 50% | 100% |
| B71 | 100% | 100% | B63 | 50% | 100% | | | | B53 | 50% | 100% |
| B72 | 100% | 100% | B75 | 50% | 100% | | | | B55 | 50% | 100% |
| B75 | 100% | 100% | A24 | 50% | 50% | | | | B57 | 50% | 100% |
| B78 | 100% | 100% | B13 | 50% | 50% | | | | B58 | 50% | 100% |
| B51 | 100% | 75% | | | | | | | B59 | 50% | 100% |
| A11 | 50% | 100% | | | | | | | B60 | 50% | 100% |
| A23 | 50% | 100% | | | | | | | B62 | 50% | 100% |
| A25 | 50% | 100% | | | | | | | B63 | 50% | 100% |
| A26 | 50% | 100% | | | | | | | B72 | 50% | 100% |
| A29 | 50% | 100% | | | | | | | B78 | 50% | 100% |

Table 21. Summary of the 548th Serum Exchange (Serum #1185-1188) by Luminex and Other - class II

| Method: Luminex | | | | | | | | | | | |
|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 24 typing Labs | | | 24 typing Labs | | | 24 typing Labs | | | 24 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| DR18 | 95% | 100% | DQ9 | 100% | 100% | DQ2 | 100% | 100% | DR4 | 100% | 100% |
| DR17 | 89% | 100% | DR7 | 100% | 100% | DR12 | 100% | 100% | DR53 | 100% | 41% |
| DR52 | 74% | 33% | DR9 | 100% | 100% | DR7 | 100% | 100% | DP14 | 11% | 100% |
| DR13 | 37% | 100% | DR12 | 100% | 88% | DR9 | 100% | 100% | DPW5 | 11% | 100% |
| DR14 | 37% | 33% | DQ7 | 100% | 76% | DR52 | 100% | 66% | DR16 | 11% | 100% |
| DR11 | 21% | 100% | DQ8 | 100% | 75% | DR18 | 79% | 100% | DR1 | 5% | 100% |
| DPW1 | 11% | 100% | DR52 | 95% | 55% | DR17 | 37% | 100% | DQ7 | 5% | 40% |
| DQ4 | 11% | 100% | DPW5 | 26% | 100% | DR13 | 32% | 100% | | | |
| DQ5 | 11% | 100% | DP10 | 21% | 100% | DR14 | 21% | 100% | | | |
| DQ6 | 11% | 100% | DP9 | 21% | 100% | DQ9 | 21% | 33% | | | |
| DQ7 | 11% | 100% | DPW1 | 21% | 100% | DQ7 | 21% | 20% | | | |
| DQ8 | 11% | 100% | DP13 | 16% | 100% | DR11 | 11% | 100% | | | |
| DQ9 | 11% | 100% | DP14 | 16% | 100% | DPW6 | 5% | 100% | | | |
| DR7 | 5% | 100% | DP17 | 11% | 100% | DR8 | 5% | 100% | | | |
| | | | DPW3 | 11% | 100% | | | | | | |
| | | | DPW6 | 11% | 100% | | | | | | |

| Method: Other | | | | | | | | | | | |
|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| DR17 | 50% | 100% | DQ7 | 50% | 100% | DQ2 | 50% | 100% | DR4 | 50% | 100% |
| DR18 | 50% | 100% | DQ8 | 50% | 100% | DR12 | 50% | 100% | | | |
| | | | DQ9 | 50% | 100% | DR7 | 50% | 100% | | | |
| | | | DR7 | 50% | 100% | DR9 | 50% | 100% | | | |
| | | | DR9 | 50% | 100% | | | | | | |

Other = Luminex PRA

Table 22. Summary of the 548th Serum Exchange (Serum #1185-1188) by NIH-Ext, Flow Cytometry, and C1q - class II

| Method: NIH-Extended | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| no consensus | | | no antigens assigned | | | no antigens assigned | | | no consensus | | |

| Method: Flow Cytometry | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| no antigens assigned | | | no antigens assigned | | | no antigens assigned | | | no antigens assigned | | |

| Method: C1q | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1185 *** | | | *** Serum 1186 *** | | | *** Serum 1187 *** | | | *** Serum 1188 *** | | |
| 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | | 1 typing Lab | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| NT | | | NT | | | no consensus | | | NT | | |

Table 23. Individual laboratory results for Serum #1185-#1188 by NIH-Standard and NIH-Extended - class I

| Investigator | **** Serum 1185 **** | | | | | | **** Serum 1186 **** | | | | | **** Serum 1187 **** | | | | | **** Serum 1188 **** | | | | Method |
|-------------------|----------------------|-----|-----|-----|-----|-------|----------------------|-----|-----|-----|-------|----------------------|-----|----|-------|-------|----------------------|-------|-----|--|--------|
| | % POS | B57 | B62 | B15 | B17 | Other | % POS | A25 | B17 | B57 | Other | % POS | B13 | B7 | Other | % POS | B13 | Other | | | |
| Claas, F.H.J. | 17 | + | + | | | | 4 | | | | | 21 | + | + | | 8 | + | | STD | | |
| Thornton, Alycia | | + | + | | | | | | + | | | | + | | | | + | | STD | | |
| Vasilescu, Rodica | 22 | | | + | + | | 10 | | | + | | 5 | + | | | 0 | | | STD | | |
| Watson, Narelle | 21 | + | + | | | | 13 | + | | | | 9 | + | | | 7 | + | | STD | | |

| Investigator | **** Serum 1185 **** | | | | | | **** Serum 1186 **** | | | | | **** Serum 1187 **** | | | | | **** Serum 1188 **** | | | | Method |
|---------------------|----------------------|-----|-----|-----|-----|-----|----------------------|-------|-----|-----|-------|----------------------|-----|-------|-------|-----|----------------------|-------|-----|--|--------|
| | % POS | B57 | B63 | B75 | B62 | B76 | Other | % POS | B57 | A25 | Other | % POS | B13 | Other | % POS | B13 | B61 | Other | | | |
| Fort, Marylise | 29 | + | + | + | + | + | B77,B46 | 15 | + | + | | 0 | | | 3 | + | | | EXT | | |
| Lardy, N.M. | 20 | + | + | + | + | | | 15 | | + | A33 | 13 | | | 24 | + | + | B60 | EXT | | |
| Reed, Elaine F. PhD | 26 | + | + | + | + | + | | 14 | + | | B58 | 6 | + | | 14 | + | + | | EXT | | |

Table 24. Individual laboratory results for Serum #1185-#1188 by Antiglobulin and C1q - class I

| | **** Serum 1185 **** | | | | | | | | | | | | | | | **** Serum 1186 **** | | | | | | | | | | | | | | |
|-------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|--|-------|----------------------|-----|-----|-----|-----|-----|-------|-----|----|--|--|--|--|-------|--------------|
| Investigator | % POS | B15 | B17 | B21 | B46 | B62 | B63 | B70 | B50 | B57 | B55 | B56 | B7 | | Other | % POS | A25 | B57 | B58 | A26 | A32 | A6601 | B17 | A2 | | | | | Other | Method |
| Hahn, Amy B. PhD | | | | | + | + | + | | + | + | + | + | + | | | | + | + | + | + | + | + | | + | | | | | | Antiglobulin |
| Vasilescu, Rodica | 27 | + | + | + | | | | + | | | | | | | | 20 | + | | | | | | + | | | | | | | Antiglobulin |

| | **** Serum 1187 **** | | | | | | | | | | | | | | | **** Serum 1188 **** | | | | | | | | | | | | | | |
|-------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|-------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|--------------|
| Investigator | % POS | B13 | B41 | B49 | B45 | A30 | B44 | B51 | A31 | B50 | | | | | Other | % POS | B13 | B21 | B40 | B41 | B47 | B49 | B50 | B60 | B61 | B45 | B12 | B44 | Other | Method |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | | | | | | | + | + | + | + | + | + | + | + | + | + | + | + | | Antiglobulin |
| Vasilescu, Rodica | 5 | + | | | | | | | | | | | | | | 5 | + | | | | | | | | | | | | | Antiglobulin |

| | **** Serum 1185 **** | | | | | | | | | | | | | | | **** Serum 1186 **** | | | | | | | | | | | | | | | | | | |
|------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----------------------|-----|-----|-----|-----|-----|-----|-------------|-------|-----|-----|-----|--|--|--|--|-------|--------|-----|
| Investigator | % POS | B13 | B35 | B44 | B45 | B46 | B49 | B50 | B51 | B52 | B63 | B56 | B57 | B58 | B62 | B63 | B71 | B72 | B75 | B76 | B77 | B78 | Other | % POS | A25 | B57 | B58 | | | | | Other | Method | |
| Phelan, Donna L. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A1,Cw10,Cw9 | | + | + | + | | | | | | | C1q |

| | **** Serum 1187 **** | | | | | | | | | | | | | | | **** Serum 1188 **** | | | | | | | | | | | | | | | |
|------------------|----------------------|-----|--|--|--|--|--|--|--|--|--|--|--|--|-------|----------------------|-----|-----|--|--|--|--|--|--|--|--|--|--|-------|--------|-----|
| Investigator | % POS | B13 | | | | | | | | | | | | | Other | % POS | B13 | B49 | | | | | | | | | | | Other | Method | |
| Phelan, Donna L. | | + | | | | | | | | | | | | | | | + | + | | | | | | | | | | | | | C1q |

Table 25. Individual laboratory results for Serum #1185-#1188 by Other - class I

| | **** Serum 1185 **** | | | | | | | | | | | | | | **** Serum 1186 **** | | | | | | | | | | | | | | | | |
|---------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----------------------|-------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------------------|-----------------|
| Investigator | % POS | B13 | B35 | B46 | B49 | B50 | B53 | B56 | B57 | B58 | B63 | B72 | B75 | B77 | Other | % POS | A11 | A2 | A25 | A29 | A31 | A32 | A33 | A34 | A66 | A68 | A74 | B57 | B58 | Other | Method |
| Martinho, Paiva & | | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,A24,B13,B27 > | Other |
| Phelan, Donna L. | 98 | | | | | | | | | | | | | | | 89 | | | | | | | | | | | | | | | Other - LMX PRA |
| Reed, Elaine F. PhD | 98 | + | + | + | + | + | + | + | + | + | + | + | + | + | B62 | 84 | + | + | + | + | + | + | + | + | + | + | + | + | + | A26 | Other - LMX PRA |

| | **** Serum 1187 **** | | | | | | | | | | | | | | **** Serum 1188 **** | | | | | | | | | | | | | | | | |
|---------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|----------------------|-------|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|-------------------|-----------------|
| Investigator | % POS | A30 | A31 | B13 | B41 | B45 | B47 | B49 | B50 | B60 | B61 | | | | Other | % POS | B13 | B45 | B47 | B49 | B50 | B60 | B61 | | | | | | | Other | Method |
| Martinho, Paiva & | | + | + | + | + | + | + | + | + | + | + | | | | CW6,B44,B51,B52 > | | + | + | + | + | + | + | + | | | | | | | CW6,A11,B51,B52 > | Other |
| Phelan, Donna L. | 45 | | | | | | | | | | | | | | | 87 | | | | | | | | | | | | | | | Other - LMX PRA |
| Reed, Elaine F. PhD | 50 | + | + | + | + | + | + | + | + | + | + | | | | | 90 | + | + | + | + | + | + | + | | | | | | | B41 | Other - LMX PRA |

Table 26. Individual laboratory results for Serum #1185 by Luminex - class I

| | | **** Serum 1185 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|-------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|-------------------|-------------------|-----|
| Investigator | % POS | A1 | A23 | A25 | A29 | A36 | A43 | A80 | B13 | B35 | B37 | B41 | B42 | B44 | B45 | B46 | B49 | B50 | B51 | B52 | B53 | B55 | B56 | B58 | B59 | B67 | B38 | B57 | B62 | B63 | B71 | B75 | B76 | B77 | CW15 | CW18 | Other | Method | |
| Arnold, Paula PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Bengochea, Carrette | 59 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A24,B78 > | LMX | |
| Cecka, J. Michael PhD | 91 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A11,A24,A66,B78 > | LMX | |
| Chen, Dong-Feng PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A24,B60 > | LMX | |
| Dunckley, Heather | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Eckels/CPMC, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Fort, Marylise | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Hamdi, Nuha | 93 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Holdsworth, Rhonda | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Lardy, N.M. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Libyh/Roulin, Tabary | 95 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A24,B61 > | LMX | |
| Loewenthal, Ron M | 64 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX | |
| Martinho, Paiva & | NT | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX | |
| McCoy, Heather | 61 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Pancoska, Carol PhD | 77 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Permpikul, Vejbaesy | 61 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Phelan, Donna L. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Reed, Elaine F. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,B60 > | LMX |
| Rosen-Bronson, Sai | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Thornton, Alycia | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Vasilescu, Rodica | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A24,B60 > | LMX |
| Vather/JHB, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |
| Vather/Pinetown, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,CW6,A11,A24 > | LMX |

Table 27. Individual laboratory results for Serum #1186 by Luminex - class I

| Investigator | **** Serum 1186 **** | | | | | | | | | | | | | | | | | | | | | | | | | | Method | | | | | | | | | | | | | | | | | | | | |
|----------------------|----------------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------|----|-------|-------|-------|-------|-----|------|-------|-------|---|-----------|-----|-----|-------------------|-----|-----|---------------------|-----|-----|-----|
| | % POS | A2 | A25 | A29 | A31 | A32 | A33 | A34 | A68 | A74 | B57 | B58 | B63 | A69 | A26 | A43 | A30 | A11 | A66 | A24 | A36 | B75 | A23 | B62 | B76 | B77 | | A1 | A6601 | A6602 | A1101 | A1102 | B13 | A203 | A2403 | Other | | | | | | | | | | | |
| Arnold, Paula PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | | | | |
| Bengochea, Carrette | 32 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | | | |
| Cecka, J. Michael P | 85 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | | | |
| Chen, Dong-Feng P | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | | |
| Dunckley, Heather | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | |
| Eckels/CPMC, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | |
| Fort, Marylise | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW16,CW17 | | LMX | | | | | | | |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | |
| Hamdi, Nuha | 85 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | | |
| Holdsworth, Rhonda | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | B46 | | LMX | | | | | | |
| Lardy, N.M. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | |
| Libyh/Roulin, Tabary | 85 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | | |
| Loewenthal , Ron M | 32 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | |
| Martinho, Paiva & | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,B27,A80,B64 > | | LMX | | | | |
| McCoy, Heather | 30 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | |
| Pancoska, Carol Ph | 42 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | | |
| Permpikul, Vejbaesy | 29 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX | | | | |
| Phelan, Donna L. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | | |
| Reed, Elaine F. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | | |
| Rosen-Bronson, Sai | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | |
| Thornton, Alycia | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX | |
| Vasilescu, Rodica | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX |
| Vather/JHB, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,B46,CW16,CW17 > | | LMX | |
| Vather/Pinetown, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW4,B46,CW16,CW17 > | | LMX | |

Table 28. Individual laboratory results for Serum #1187 by Luminex - class I

| | | **** Serum 1187 **** | | | | | | | | | | | | | | | | | | | | |
|-----------------------|-------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-------|----------------|-----|
| Investigator | % POS | A30 | A31 | B13 | B41 | B45 | B47 | B49 | B50 | B44 | B60 | B61 | B51 | B59 | CW6 | B52 | CW18 | B53 | B77 | Other | Method | |
| Arnold, Paula PhD | | + | + | + | + | + | + | + | + | + | + | + | | | + | | | | | | | LMX |
| Bengochea, Carretto | 17 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | LMX |
| Cecka, J. Michael PhD | 44 | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | | LMX |
| Chen, Dong-Feng PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A80 | LMX |
| Dunckley, Heather | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX |
| Eckels/CPMC, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Fort, Marylise | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Hamdi, Nuha | 44 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Holdsworth, Rhonda | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX |
| Lardy, N.M. | | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | LMX |
| Libyh/Roulin, Tabary | 44 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Loewenthal , Ron M | 16 | + | + | + | + | + | + | + | + | + | | | + | + | | | | | | | B40 | LMX |
| Martinho, Paiva & | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | B7,A32,B64,B63 | LMX |
| McCoy, Heather | 21 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Pancoska, Carol PhD | 25 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX |
| Permpikul, Vejbaesy | 22 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX |
| Phelan, Donna L. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Reed, Elaine F. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | LMX |
| Rosen-Bronson, Sal | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX |
| Thornton, Alycia | | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | LMX |
| Vasilescu, Rodica | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX |
| Vather/JHB, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | | LMX |
| Vather/Pinetown, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A80 | LMX |

Table 29. Individual laboratory results for Serum #1188 by Luminex - class I

| | | **** Serum 1188 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|-------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------------------------|---------------------|-------------------|-------------------|-----|
| Investigator | % POS | B13 | B45 | B47 | B49 | B41 | B44 | B50 | B51 | B60 | B61 | B27 | B7 | B57 | B62 | B76 | B77 | B72 | B52 | B53 | B71 | B35 | B59 | B38 | B63 | B75 | B37 | B39 | B48 | B56 | B81 | B58 | B73 | B78 | A43 | B46 | Other | Method | | | |
| Arnold, Paula PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | | + | | | | | | B8101,B2708 | LMX | | | |
| Bengochea, Carrette | 38 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | | | | | B703,B8101,B2708,B7801 > | LMX | | | |
| Cecka, J. Michael PhD | 56 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | | | | | BW4 | LMX | | | |
| Chen, Dong-Feng PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | | | | | B54,B55,B67,B18 > | LMX | | |
| Dunckley, Heather | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,B54,B55,B67 > | LMX | | |
| Eckels/CPMC, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | B67,BW4,B2708,A6602 | LMX | | |
| Fort, Marylise | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,B55,B67,B18 | LMX | | |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,BW4 | LMX | | |
| Hamdi, Nuha | 75 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,A26 | LMX | | | |
| Holdsworth, Rhonda | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,B54,B55,B67 > | LMX | | |
| Lardy, N.M. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | B2708 | LMX | | |
| Libyh/Roulin, Tabary | 47 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A26,B8101,BW4,B2708 > | LMX | | | |
| Loewenthal , Ron M | 33 | + | + | + | + | + | + | | | | | + | | | | | | | | + | | | | + | | | | | | | | | | | | | B40,B15 | LMX | | | |
| Martinho, Paiva & | | + | + | + | + | | | + | + | + | + | | + | + | | | | | | + | | | | + | | | | | | | | | | | | | | CW6,A11,A1,A30 > | LMX | | |
| McCoy, Heather | 35 | + | + | + | + | + | + | | + | + | + | + | + | + | + | + | + | + | | | + | + | | | | | + | + | | | + | | | | | | | | LMX | | |
| Pancoska, Carol PhD | 53 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX | | |
| Permpikul, Vejbaesy | 38 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX | | |
| Phelan, Donna L. | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX | | |
| Reed, Elaine F. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A6602 | LMX | |
| Rosen-Bronson, Sal | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,B54,B55,B67 > | LMX | |
| Thornton, Alycia | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX | |
| Vasilescu, Rodica | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW6,B54,B55,B67 > | LMX | |
| Vather/JHB, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | A66,B54,B55,B67 > | LMX | |
| Vather/Pinetown, | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | CW6,A66,B54,B55 > | LMX |

Table 30. Individual laboratory results for Serum #1185 - #1188 by Flow Cytometry and Elisa - class I

| Investigator | **** Serum 1185 **** | | | | | | | | | | | | | | | | | | | **** Serum 1186 **** | | | | | | | | Method | | | | | | | |
|------------------|----------------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----------------------|-----|-----|-----|-----|--------------|-------|-----|--------|-----|-----|-----|----|-------|--------------|-------|
| | % POS | A1 | B13 | B35 | B37 | B41 | B44 | B45 | B46 | B49 | B50 | B52 | B53 | B55 | B56 | B57 | B58 | B62 | B63 | B71 | B72 | B75 | B78 | B51 | Other | % POS | A25 | | A26 | B57 | B58 | A2 | Other | | |
| Eckels/CPMC | 96 | | | | | | | | | | | | | | | | | | | | | | | | | 96 | | | | | | | | FC | |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | + | + | + | + | | | Elisa | |
| McCoy, Heather | 62 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | A11,A24,B60> | 45 | + | + | + | + | + | | | A11,A24,A66> | Elisa |

| Investigator | **** Serum 1187 **** | | | | | | | | | | | | | | | | | | | **** Serum 1188 **** | | | | | | | | | Method | | | | |
|------------------|----------------------|-----|-----|-----|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----------------------|--------------|-----|-----|-----|-----|-----|-----|-----|--------|-----|-------|--------------|-------|
| | % POS | B13 | B41 | B44 | B45 | | | | | | | | | | | | | | | Other | % POS | B13 | B41 | B44 | B45 | B50 | B61 | B75 | | B49 | Other | | |
| Eckels/CPMC | 63 | | | | | | | | | | | | | | | | | | | | Other | 96 | | | | | | | | | | FC | |
| Hahn, Amy B. PhD | | + | + | + | + | | | | | | | | | | | | | | | | | | + | + | + | + | + | + | + | + | | Elisa | |
| McCoy, Heather | 21 | + | + | + | + | | | | | | | | | | | | | | | | B60,B61,B49> | 51 | + | + | + | + | + | + | + | + | | B60,B48,A66> | Elisa |

Table 29. Individual laboratory results for Serum #1185 - #1186 by Luminex - class II

| Investigator | **** Serum 1185 **** | | | | | | | | | | | | | | **** Serum 1186 **** | | | | | | | | | | | | | | Method | | | | | | |
|----------------------|----------------------|------|------|------|------|------|------|------|-----|-----|-----|-----|-----|-----|---------------------------|-------|-----|-----|-----|------|-----|-----|------|------|------|-----|------|------|--------|------|------|------|------------|--------------------------------|-----|
| | % POS | DR18 | DR17 | DR52 | DR13 | DR14 | DR11 | DPW1 | DQ4 | DQ5 | DQ6 | DQ7 | DQ8 | DQ9 | Other | % POS | DQ9 | DR7 | DR9 | DR12 | DQ7 | DQ8 | DR52 | DPW5 | DP10 | DP9 | DPW1 | DP13 | | DP14 | DP17 | DPW3 | DPW6 | Other | |
| Arnold, Paula PhD | | + | + | + | | | | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | | LMX |
| Bengochea, Carrette | 28 | | | | | | | | + | + | + | + | + | + | | 21 | + | + | + | + | + | + | | | | | | | | | | | | | LMX |
| Cecka, J. Michael P | 26 | + | + | | | | | | | | | | | | 51 | + | + | + | + | + | + | | | | | | | | | | | | | | LMX |
| Chen, Dong-Feng P | | + | + | + | + | + | | | | | | | | | | | + | + | + | + | + | + | | + | + | | | | | | | | DQA1*02:01 | LMX | |
| Dunckley, Heather | | + | + | + | | | | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | LMX | |
| Eckels/CPMC, | | + | + | + | | | | | | | | | | | DRB3*01 | | + | + | + | + | + | + | | | | | | | | | | | | DRB3*01,*03 | LMX |
| Fort, Marylise | | + | + | + | + | + | + | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | LMX | |
| Hahn, Amy B. PhD | | + | + | | | | | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | LMX | |
| Hamdi, Nuha | 34 | + | + | + | + | + | | | | | | | | | 49 | + | + | + | + | + | + | | | | | | | | | | | | | LMX | |
| Holdsworth, Rhonda | | | | | | | | | | | | | | | DRB3*01:01+ | | + | + | + | + | + | + | | | | | | | | | | | | DP18, DRB3*01:01, *03:01 | LMX |
| Libyh/Roulin, Tabary | 26 | + | + | | | | | | | | | | | | | 69 | + | + | + | + | + | + | | + | + | | | | | | | | | | LMX |
| Pancoska, Carol Ph | 13 | + | + | + | | | | | | | | | | | 40 | + | + | + | + | + | + | | | | | | | | | | | | | | LMX |
| Permpikul, Vejbaesy | 3 | + | + | + | | | | | | | | | | | 19 | + | + | + | + | + | + | | | | | | | | | | | | | | LMX |
| Phelan, Donna L. | | + | + | + | | | | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | | LMX |
| Reed, Elaine F. PhD | | + | + | + | + | + | | | | | | | | | | | + | + | + | + | + | + | | | | | | | | | | | | DRB3*01:01, *03:01 | LMX |
| Rosen-Bronson, Sari | | + | + | + | | | | | | | | | | | DRB3*01:01, DRB3*03:01 | | + | + | + | + | + | + | + | + | | | + | + | | | | | | DRB3*01:01, *03:01 | LMX |
| Thornton, Alycia | | + | | | | | + | | + | + | + | + | + | + | | | + | + | + | + | + | + | | | | | | | | | | | | | LMX |
| Vather/JHB, | | + | + | + | + | + | + | | | | | | | | DR7 | | + | + | + | + | + | + | + | + | + | + | + | + | | | | | + | | LMX |
| Vather/Pinetown, | | + | + | + | + | + | | | | | | | | | | | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | DP19 | LMX |

Table 30. Individual laboratory results for Serum #1187 - #1188 by Luminex - class II

| Investigator | **** Serum 1187 **** | | | | | | | | | | | | **** Serum 1188 **** | | | | | | Method | | | |
|----------------------|----------------------|-----|------|-----|-----|------|------|------|------|------|-----|-----|------------------------|-------|-----|------|------|------|--------|------|-------|-----|
| | % POS | DQ2 | DR12 | DR7 | DR9 | DR52 | DR18 | DR17 | DR13 | DR14 | DQ9 | DQ7 | Other | % POS | DR4 | DR53 | DP14 | DPW5 | | DR16 | Other | |
| Arnold, Paula PhD | | + | + | + | + | + | | | | | | | | | + | + | | | | | | LMX |
| Bengochea, Carrette | 21 | + | + | + | + | + | | | + | + | | | DR11 | 10 | + | + | | | + | | | LMX |
| Cecka, J. Michael P | 57 | + | + | + | + | + | | | | | | | | 17 | + | + | | | | | | LMX |
| Chen, Dong-Feng P | | + | + | + | + | + | + | + | + | + | | | DQA1*02:01 | | + | + | | | | | | LMX |
| Dunckley, Heather | | + | + | + | + | + | + | + | + | | + | + | | | + | + | | | | | | LMX |
| Eckels/CPMC, | | + | + | + | + | + | + | | | | | | | | + | + | | | | | | LMX |
| Fort, Marylise | | + | + | + | + | + | + | + | | | | | | | + | + | | | | | | LMX |
| Hahn, Amy B. PhD | | + | + | + | + | + | + | | | | | + | + | | + | + | | | | | | LMX |
| Hamdi, Nuha | 54 | + | + | + | + | + | + | | | | | + | + | 17 | + | + | + | | | DQ7 | | LMX |
| Holdsworth, Rhonda | | + | + | + | + | + | + | + | | | | | DRB1*13:03, DQA1*02 | | + | + | + | + | | | | LMX |
| Libyh/Roulin, Tabary | 54 | + | + | + | + | + | + | | | | | | | 17 | + | + | | | | | | LMX |
| Pancoska, Carol Ph | 27 | + | + | + | + | + | + | | | | | | | 9 | + | + | | | | | | LMX |
| Permpikul, Vejbaesy | 17 | + | + | + | + | + | + | | | | | | | 7 | + | + | | | | | | LMX |
| Phelan, Donna L. | | + | + | + | + | + | + | | | | | | | | + | + | | + | | | | LMX |
| Reed, Elaine F. PhD | | + | + | + | + | + | + | | | | | | DQA1*02 | | + | + | | | | | | LMX |
| Rosen-Bronson, Sa | | + | + | + | + | + | + | + | + | | + | + | | | + | + | | | | | | LMX |
| Thornton, Alycia | | + | + | + | + | + | | | | | | | | | + | + | | | + | DR1 | | LMX |
| Vather/JHB, | | + | + | + | + | + | + | + | + | + | | | | | + | + | | | | | | LMX |
| Vather/Pinetown, | | + | + | + | + | + | + | + | + | + | | | DR8,DR11 | | + | + | | | | | | LMX |

Table 31. Individual laboratory results for Serum #1185 - #1188 by various methods - class II

| Investigator | **** Serum 1185 **** | | | | **** Serum 1186 **** | | | | | | | **** Serum 1187 **** | | | | | | **** Serum 1188 **** | | | Method |
|---------------------|----------------------|------|------|-------|----------------------|-----|-----|-----|-----|-----|-------|----------------------|-----|-----|-----|------|-------|----------------------|-----|-------|---------|
| | % POS | DR17 | DR18 | Other | % POS | DQ7 | DQ8 | DQ9 | DR7 | DR9 | Other | % POS | DQ2 | DR7 | DR9 | DR12 | Other | % POS | DR4 | Other | |
| Eckels/CPMC | 67 | | | | 70 | | | | | | | 87 | | | | | | 19 | | | FC |
| Phelan, Donna L. | NT | | | | NT | | | | | | | | + | + | | | | NT | | | C1q |
| Phelan, Donna L. | 34 | | | | 71 | | | | | | | 74 | | | | | | 17 | | | LMX PRA |
| Reed, Elaine F. PhD | 37 | + | + | | 57 | + | + | + | + | + | | 47 | + | + | + | + | | 13 | + | | LMX PRA |
| Reed, Elaine F. PhD | 52 | | | | 11 | | | | | | | 9 | | | | | | 13 | | | EXT |